Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
UK Startups and Innovation
14NOV

Alchemab wins Bank's record £25m cheque

2 min read
18:53UTC

Alchemab Therapeutics raised a £25m Series A extension on 9 July, the British Business Bank's largest-ever direct life-sciences cheque, for AI-enabled antibody discovery.

TechnologyAssessed
Key takeaway

Alchemab's £25m is the Bank's biggest life-sciences bet, staking public money on AI antibody discovery.

Alchemab Therapeutics, a British antibody-discovery biotech, raised a £25m Series A extension on 9 July, the largest direct life-sciences investment the British Business Bank has ever made, to push an AI-enabled antibody-discovery pipeline toward the clinic⁠1.

Alchemab hunts for protective antibodies in people who resist diseases they should have caught, then turns those molecules into drug candidates. The method leans on machine learning to sift immune repertoires at a scale no bench scientist could match, placing it in the same AI-meets-biology tier as IMU Biosciences, which raised £40m in June.

The cheque puts the state directly on a life-sciences cap table rather than behind a fund manager. For a Bank criticised for leading none of the year's marquee AI rounds, backing Alchemab plants a flag in a field where British science still leads. Someone still has to run those assays, and the government published a plan to build that workforce the same afternoon.

Deep Analysis

In plain English

Alchemab Therapeutics is a Cambridge biotech using artificial intelligence to find antibodies, proteins the immune system makes to fight disease, that could become new drugs. On 9 July it raised £25m as an extension to an earlier funding round, and all of it came from the British Business Bank, a state-owned bank that invests in growing UK companies. It is the largest single life-sciences investment the Bank has ever made directly. The money should let Alchemab keep developing its antibody candidates towards human clinical trials without needing to raise again from private investors in the near term.

Deep Analysis
Root Causes

Alchemab's cheque exists because the Bank's mandate changed in April: for the first time it can lead venture rounds and invest directly up to £60m per company, rather than only co-investing alongside private leads as it did in IMU Biosciences' £40m round.

Pre-clinical antibody discovery is capital-intensive with a long return horizon, a profile private venture funds have grown warier of funding alone since 2023; the Bank's expanded mandate exists specifically to backstop that gap in patient capital.

What could happen next?
  • Meaning

    The Bank's willingness to write £25m directly into a pre-clinical biotech signals it now treats life-sciences extension rounds as within its risk appetite, not just seed-stage deeptech.

First Reported In

Update #11 · Britain funds and defunds its own science

British Business Bank· 14 Jul 2026
Read original →
Different Perspectives
Association of Investment Companies (Richard Stone)
Association of Investment Companies (Richard Stone)
The trust industry body criticised the Budget for leaving Venture Capital Trust relief at 20%. It had lobbied for the 30% rate to return.
Tax Justice UK
Tax Justice UK
The campaign group opposed the 10% founders' rate as a giveaway to a small group of wealthy owners. It said the BADR cut should have gone further, to abolition.
techUK
techUK
The trade body set the new relief against the BADR cut, which halves the most a seller can save to £30,000. It says the Budget takes back with BADR part of what it gives founders.
Startup Coalition
Startup Coalition
The founder lobby group welcomed the Budget package for startups. It treats the new relief as the strongest government support for founders in years.
HM Treasury
HM Treasury
The Treasury created a 10% founders' relief on up to £10m of lifetime gains and expects about 600 people a year to use it. It says the relief rewards founders behind the UK's fastest-growing companies.
Abu Dhabi Investment Council
Abu Dhabi Investment Council
The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.